Prostate Cancer, Version 1.2014

Mohler, James L.; Kantoff, Philip W.; Armstrong, Andrew J.; Bahnson, Robert R.; Cohen, Michael B.; D’Amico, Anthony V.; Eastham, James A.; Enke, Charles Arthur; Farrington, Thomas; Higano, Celestia S.; Horwitz, Eric M.; Kawachi, Mark H.; Kuettel, Michael; Lee, Richard J.; MacVicar, Gary R.; Malcolm, Arnold W.; Miller, David C.; Plimack, Elizabeth R.; Pow‐Sang, Julio M.; Richey, Sylvia; Roach, Mack; Rohren, Eric M.; Rosenfeld, Stan; Small, Eric J.; Srinivas, Sandy; Stein, C. A.; Strope, Seth A.; Tward, Jonathan D.; Walsh, Patrick C.; Shead, Dorothy A.; Ho, Maria M.

doi:10.6004/jnccn.2013.0174

Cited by 261 publications

(332 citation statements)

References 22 publications

(25 reference statements)

Supporting

Mentioning

313

Contrasting

Unclassified

Order By: Relevance

“…Given definite evidence of osseous metastasis, plans for post-PET chemotherapy and radiotherapy were more common in nonprostate cancer cases than in prostate cancer cancers. This finding is consistent with treatment guidelines-that is, in prostate cancer osseous symptoms may respond adequately to hormone therapy whereas pain from osseous metastases may require more aggressive palliation in other cancers (5,25,26).…”

Section: Impact Of Imaging For Suspected Fomsupporting

confidence: 82%

Impact of¹⁸F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry

et al. 2014

View full text Add to dashboard Cite

The National Oncologic PET Registry prospectively assessed the impact of PET with 18 F-sodium fluoride (NaF PET) on intended management of Medicare patients with suspected or known osseous metastasis. We report our findings for cancers other than prostate and make selected comparisons to our previously reported prostate cancer cohort. Methods: Data were collected from both referring and interpreting physicians before and after NaF PET in patients (age ≥ 65 y) stratified for initial staging (IS; n 5 570), for suspected first osseous metastasis (FOM; n 5 1,814; breast, 781 [43%]; lung, 380 [21%]; and all other cancers, 653 [36%]), and for suspected progression of osseous metastasis (POM; n 5 435). Results: The dominant indication was bone pain. If NaF PET were unavailable, conventional bone scintigraphy would have been ordered in 85% of patients. In IS, 28% of patients had suspected or confirmed nonosseous metastasis. If neither conventional bone scintigraphy nor NaF PET were available, referring physicians would have ordered other advanced imaging more than 70% of the time rather than initiate treatment for suspected FOM (11%-16%) or POM (18%-22%). When intended management was classified as either treatment or nontreatment, the intended management change for each cancer type was highest in POM, lower in IS, and lowest in FOM. For suspected FOM, intended management change was lower in breast (24%), lung (36%), or other cancers (31%), compared with prostate cancer (44%) (P , 0.0001), but the NaF PET finding (normal/benign/equivocal, probable, or definite metastases) frequencies were similar across cancer types. After normal/benign/ equivocal PET results, 15% of breast, 30% lung, and 38% prostate cancer patients had treatment, likely reflecting differences in management of nonosseous disease. For patients with definite metastasis on NaF PET, nonprostate, compared with prostate, cancer patients had post-PET plans for more frequent biopsy, alternative imaging, chemotherapy, and radiotherapy. In the smaller IS and POM cohorts, differences among cancer types were not significant. Conclusion: Overall, NaF PET led to change in intended management in a substantial fraction of nonprostate cancer patients. In the setting of suspected FOM, NaF PET had a lower immediate impact on the treat/nontreat decision in nonprostate versus prostate cancer patients, which is consistent with current practice guidelines.

show abstract

Section: Impact Of Imaging For Suspected Fomsupporting

confidence: 82%

Impact of¹⁸F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Patients who are unlikely to have metastasis are better off avoiding these costly and potentially harmful procedures. PSA level has been used to predict bone metastases and select patients for bone scans (16). Although our data also showed a strong association between PSA and metastasis and none of the CTC analyses taken alone outperformed PSA for metastatic correlation, a CRS based on both PSA level and EMTing CTC count significantly improved the metastasis prediction accuracy compared with PSA alone.…”

Section: Discussionmentioning

confidence: 67%

The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis

Mao

Guo

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To develop an approach for the investigation of different subtypes of circulating tumor cells (CTC) and other cells to evaluate their potential prognostic value of prostate cancer.Experimental Design: Malignancy of CTCs undergoing epithelial-to-mesenchymal transition (EMT) was confirmed by repeated FISH. Subgroups of CTCs in 81 patients with prostate cancer (43 castration resistant and 38 untreated localized) were correlated to disease aggressiveness parameters. AUC analysis was applied to compare the performance for metastasis prediction between serum PSA level alone and a combined risk score using both PSA and EMTing CTC count. Circulating megakaryocytes and cancer patient survival association was performed using Cox model.Results 0).Conclusions: This CTC analysis approach and the potential association of megakaryocytes with cancer prognosis may greatly enhance our ability to investigate the cancer metastasis process and to predict/monitor cancer progression.

show abstract

“…According to commonly cited stratification schemes used to guide treatment recommendations and predict prostate cancer recurrence, our patient was considered to be at intermediate risk [4,5]. He opted for definitive radiotherapy, and his cancer was successfully treated with a standard radiation dosing and fractionation schedule.…”

Section: Discussionmentioning

confidence: 99%

Delayed radiation-induced lumbosacral radiculoplexus neuropathy – a diagnostic dilemma

Domingo-Horne¹

2017

Neurol Disord Therap

View full text Add to dashboard Cite

The delayed effects of neurotoxicity related to radiation therapy present a diagnostic challenge. It is essential for clinicians to recognize radiation-induced radiculoplexus neuropathy, which should also be discussed with patients as a potential iatrogenic complication of cancer treatment. CaseA 70-year-old gentleman presented to our EMG laboratory in early 2015 for recurrent episodes of right lower extremity "buckling" and falls. His symptoms were gradual in onset and had been worsening over several weeks. His past medical history included ankylosing spondylitis, a decade-long history of poorly controlled diabetes mellitus (most recent HbA1c at that time 8.2%), and remote prostate adenocarcinoma (T1c with perineural invasion, Gleason 3+4, PSA 4.36), for which he had received definitive radiotherapy in early 2008 (45 Gy whole pelvis, followed by serial coned-down boosts to the prostate and seminal vesicles; total dose 75.6 Gy). Radiotherapy was complicated by recurrent prostatitis, radiation-induced enteritis, and an associated partial small bowel obstruction in 2014.He was found to have severe proximal right lower extremity weakness, with near-inability to flex at the hip or extend at the knee. There was moderate weakness in hip abduction and adduction noted, while knee flexion, ankle dorsiflexion, and ankle plantar flexion were preserved and unaffected. There was an area of hypesthesia along the right upper anterior thigh, as well as length-dependent bilateral lower extremity sensory loss and hyporeflexia. The distal lower extremities were edematous. The remainder of his neurological and general medical examinations at that time were unremarkable. An EMG was performed (Tables 1 and 2), with abnormalities taken within clinical context concerning for a severe proximal right lumbosacral radiculoplexopathy and underlying sensorimotor axon loss-predominant peripheral polyneuropathy.He was admitted for additional workup and treatment. A pelvic MRI was notable for a T2/STIR hyperintense signal abnormality and enhancement involving the right pectineus, adductor magnus, iliacus, and psoas muscles, and faint enhancement of the right femoral and obturator nerves (Figure 1). For a presumed diagnosis of diabetic amyotrophy, he received 12 weeks of intravenous methylprednisolone and inpatient rehabilitation.He was lost to follow-up until early 2016, when he presented with progressively worsening painless right leg weakness. He reported no subjective improvement either during or following his earlier treatment course with corticosteroids. His interim glycemic control had remained suboptimal (average HbA1c 8.5%). He otherwise denied any significant change in his weight or general medical wellbeing. On reevaluation, he was found to have pronounced atrophy of the right quadriceps, continued proximal right leg weakness graded similarly to the year before, and the interim development of a nearcomplete right foot drop of uncertain chronicity. Sensory deficits were unchanged. The lower extremities were areflexic. A follow...

show abstract

Prostate Cancer, Version 1.2014

Cited by 261 publications

References 22 publications

Impact of¹⁸F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry

Impact of¹⁸F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry

The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis

Delayed radiation-induced lumbosacral radiculoplexus neuropathy – a diagnostic dilemma

Contact Info

Product

Resources

About

Prostate Cancer, Version 1.2014

Cited by 261 publications

References 22 publications

Impact of18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry

Impact of18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry

The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis

Delayed radiation-induced lumbosacral radiculoplexus neuropathy – a diagnostic dilemma

Contact Info

Product

Resources

About

Impact of¹⁸F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry

Impact of¹⁸F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry